Update shared on04 Aug 2025
Fair value Decreased 8.41%Despite improved profitability reflected in a higher net profit margin, CONMED’s valuation has compressed with a lower future P/E, leading analysts to reduce their consensus price target from $66.60 to $61.00.
What's in the News
- CONMED Corporation raised its full-year 2025 revenue guidance to a range of $1.356 billion to $1.378 billion.
- Q3 2025 revenue is expected between $330 million and $337 million, with a minor FX tailwind.
- The company was added to multiple Russell Value indexes, including the Russell 2000, 2500, 3000, and Small Cap Comp Value Benchmarks.
- CONMED was simultaneously dropped from several Russell Growth indexes, including the Russell 2000, 2500, 3000, and Small Cap Comp Growth Benchmarks.
Valuation Changes
Summary of Valuation Changes for CONMED
- The Consensus Analyst Price Target has fallen from $66.60 to $61.00.
- The Future P/E for CONMED has significantly fallen from 19.06x to 15.55x.
- The Net Profit Margin for CONMED has risen from 8.94% to 9.84%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.